Adynxx
Signal active
Organization
Contact Information
Overview
Adynxx a biopharmaceutical company, develops pain management drugs. It offers AYX1, a drug candidate to prevent acute post-operative pain and its transition into chronic pain; and AYX therapeutic programs, including long-term relief treatments for mature chronic pain syndromes. The company was incorporated in 2007 and is based in San Francisco, California.
About
Industries
Biotechnology, Pharmaceutical, Biopharma
Founded
2007
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Adynxx headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Biopharma sector. The company focuses on Biotechnology and has secured $1.1B in funding across 48 round(s). With a team of 1-10 employees, Adynxx is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Adynxx, raised $4.8M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
0
Lead Investors
0
Total Funding Amount
$23.5M
Details
2
Adynxx has raised a total of $23.5M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2017 | Early Stage Venture | 16.0M | ||
| 2011 | Early Stage Venture | 4.8M |
Investors
Adynxx is funded by 8 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Domain Associates | - | FUNDING ROUND - Domain Associates | 16.0M |
| Eric Heil | - | FUNDING ROUND - Eric Heil | 2.0M |
| Adynxx | - | FUNDING ROUND - Adynxx | 2.0M |
| Domain Associates | - | FUNDING ROUND - Domain Associates | 2.0M |
Recent Activity
There is no recent news or activity for this profile.